Prognostic factors in stage 4 neuroblastoma treated with busulphan-melphalan: Report from the European HR-NBL1/Siopen trial.

Ruth Ladenstein,Ulrike Poetschger,Martin Elliott,Roberto Luksch,Victoria Castel,Isaac Yaniv,Vassilios Papadakis,Genevieve Laureys,Josef Malis,Walentyna Balwierz,Ellen Ruud,Per Kogner,Henrik Schroeder,Ana Forjaz de Lacerda,Maja Beck Popovic,Pavel Bician,Miklós Garami,Toby Trahair,Andrew D.J. Pearson,D. Couanet

Prognostic factors in stage 4 neuroblastoma treated with busulphan-melphalan: Report from the European HR-NBL1/Siopen trial.

2016

10527Background: Evaluation of prognostic factors in high risk stage 4 neuroblastoma (HRNBL) patients (pts) treated with busulfan-melphalan (BUMEL) within HR-NBL1/SIOPEN. Methods: Between 2002-2009...

Keywords:

Neuroblastoma
Pathology
Melphalan
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations